JP5415942B2 - 処置の方法およびその処置に有用な薬剤 - Google Patents

処置の方法およびその処置に有用な薬剤 Download PDF

Info

Publication number
JP5415942B2
JP5415942B2 JP2009515675A JP2009515675A JP5415942B2 JP 5415942 B2 JP5415942 B2 JP 5415942B2 JP 2009515675 A JP2009515675 A JP 2009515675A JP 2009515675 A JP2009515675 A JP 2009515675A JP 5415942 B2 JP5415942 B2 JP 5415942B2
Authority
JP
Japan
Prior art keywords
optionally substituted
formula
compound
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009515675A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009541223A (ja
JP2009541223A5 (enExample
Inventor
アシュレー ブッシュ
ペネロペ ジェイン ハギンズ
ジャック ゴードン パーソンズ
ガイク ベン コック
ヴィジャヤ ケンチェ
Original Assignee
プラナ バイオテクノロジー リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラナ バイオテクノロジー リミティッド filed Critical プラナ バイオテクノロジー リミティッド
Publication of JP2009541223A publication Critical patent/JP2009541223A/ja
Publication of JP2009541223A5 publication Critical patent/JP2009541223A5/ja
Application granted granted Critical
Publication of JP5415942B2 publication Critical patent/JP5415942B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
JP2009515675A 2006-06-22 2007-06-22 処置の方法およびその処置に有用な薬剤 Expired - Fee Related JP5415942B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81577906P 2006-06-22 2006-06-22
US60/815,779 2006-06-22
PCT/AU2007/000876 WO2007147217A1 (en) 2006-06-22 2007-06-22 Method of treatment of glioma brain tumour

Publications (3)

Publication Number Publication Date
JP2009541223A JP2009541223A (ja) 2009-11-26
JP2009541223A5 JP2009541223A5 (enExample) 2011-02-24
JP5415942B2 true JP5415942B2 (ja) 2014-02-12

Family

ID=38833006

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009515675A Expired - Fee Related JP5415942B2 (ja) 2006-06-22 2007-06-22 処置の方法およびその処置に有用な薬剤

Country Status (9)

Country Link
US (1) US8163760B2 (enExample)
EP (1) EP2044026B1 (enExample)
JP (1) JP5415942B2 (enExample)
CN (1) CN101589026B (enExample)
AU (1) AU2007262670B2 (enExample)
CA (1) CA2656825C (enExample)
DK (1) DK2044026T3 (enExample)
ES (1) ES2474865T3 (enExample)
WO (1) WO2007147217A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
CN101987849B (zh) * 2006-04-14 2013-05-08 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性(amd)的方法
JP5419706B2 (ja) * 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
US9321730B2 (en) * 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
US8071766B2 (en) 2008-02-01 2011-12-06 Takeda Pharmaceutical Company Limited HSP90 inhibitors
GB0806794D0 (en) * 2008-04-15 2008-05-14 Ludwig Inst Cancer Res Therapeutic compounds
US9284297B2 (en) * 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
ES2634492T3 (es) 2008-12-24 2017-09-28 Prana Biotechnology Ltd Compuestos de quinazolinona
US10253020B2 (en) 2009-06-12 2019-04-09 Abivax Compounds for preventing, inhibiting, or treating cancer, AIDS and/or premature aging
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
WO2012083866A1 (en) 2010-12-22 2012-06-28 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
EP2565186A1 (en) * 2011-09-02 2013-03-06 Hybrigenics S.A. Selective and reversible inhibitors of ubiquitin specific protease 7
FR2984317B1 (fr) * 2011-12-20 2015-02-27 Univ Rennes Composes chelateurs de metal presentant au moins une chaine polyaminee.
CA2861840C (en) 2012-01-13 2020-12-15 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
PH12019502809B1 (en) 2012-06-13 2024-04-24 Incyte Holdings Corp Substituted tricyclic compounds as fgfr inhibitors
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6027267B2 (ja) * 2012-12-27 2016-11-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｏｍｔ阻害剤
EP2757161A1 (en) 2013-01-17 2014-07-23 Splicos miRNA-124 as a biomarker of viral infection
MY181497A (en) 2013-04-19 2020-12-23 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
TW201605805A (zh) * 2013-10-23 2016-02-16 Chugai Pharmaceutical Co Ltd 喹唑啉酮及異喹啉酮衍生物
EP2974729A1 (en) 2014-07-17 2016-01-20 Abivax Quinoline derivatives for use in the treatment of inflammatory diseases
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
JP6784942B2 (ja) * 2014-12-02 2020-11-18 オールテリティ セラピューティクス リミテッド ４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン化合物
PE20171514A1 (es) 2015-02-20 2017-10-20 Incyte Corp Heterociclos biciclicos como inhibidores de fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019067503A1 (en) 2017-09-26 2019-04-04 Dana-Farber Cancer Institute, Inc. NEW USP7 INHIBITORS FOR THE TREATMENT OF MULTIPLE MYELOMA
CN112867716B (zh) 2018-05-04 2024-09-13 因赛特公司 Fgfr抑制剂的固体形式和其制备方法
JP7568512B2 (ja) 2018-05-04 2024-10-16 インサイト・コーポレイション Ｆｇｆｒ阻害剤の塩
WO2019237125A1 (en) 2018-06-08 2019-12-12 The General Hospital Corporation Inhibitors of prolyl-trna-synthetase
WO2020086595A1 (en) 2018-10-22 2020-04-30 Dana-Farber Cancer Institute, Inc. Usp7 inhibition
EP3669873A1 (en) 2018-12-20 2020-06-24 Abivax Quinoline derivatives for use ine the traeatment of inflammation diseases
CN111471012B (zh) * 2019-01-23 2023-04-25 鲁南制药集团股份有限公司 一种蜈蚣喹啉类化合物、制备方法及其应用
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN110240590B (zh) * 2019-07-16 2025-09-19 广州新民培林医药科技有限公司 一类嘧啶喹啉衍生物及其制备方法和应用
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11607416B2 (en) 2019-10-14 2023-03-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AU2020394867A1 (en) 2019-12-02 2022-05-26 Storm Therapeutics Limited Polyheterocyclic compounds as METTL3 inhibitors
WO2021113462A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11753413B2 (en) 2020-06-19 2023-09-12 Incyte Corporation Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors
ES3035284T3 (en) 2020-07-02 2025-09-01 Incyte Corp Tricyclic urea compounds as jak2 v617f inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
WO2022046989A1 (en) 2020-08-27 2022-03-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CN113214249B (zh) * 2021-04-23 2023-09-19 成都大学 吡啶并[1,2-a]嘧啶-4-硫酮化合物的合成方法
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
JP2024522188A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4653053A1 (en) 2021-11-02 2025-11-26 Flare Therapeutics, Inc. Pparg inverse agonists and uses thereof
PE20251706A1 (es) 2022-03-17 2025-07-02 Incyte Corp Compuestos de urea triciclica como inhibidores de v617f de jak2
CN116410132B (zh) * 2023-02-23 2024-07-09 广东工业大学 一种8-羟基喹啉类化合物及其制备方法和在制备抗肿瘤药物上的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL145401A0 (en) * 1999-03-24 2002-06-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
AU2001230426C1 (en) * 2000-01-24 2006-06-22 Astrazeneca Ab Therapeutic morpholino-substituted compounds
WO2002060373A2 (en) * 2001-01-29 2002-08-08 Insight Strategy And Marketing Ltd Indole derivatives and their uses as heparanase inhibitors
IL159086A0 (en) * 2001-06-08 2004-05-12 Cytovia Inc 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
BR0307874A (pt) * 2002-02-20 2004-12-28 Upjohn Co Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
HK1079789A1 (zh) 2002-10-03 2006-04-13 Targegen, Inc. 血管静态毒性试剂及其使用方法
US7692011B2 (en) * 2002-10-04 2010-04-06 Prana Biotechnology Limited 8-hydroxy and 8-mercapto quinazolinones
WO2005063213A1 (en) * 2003-12-19 2005-07-14 Biodelivery Sciences International, Inc. Rigid liposomal cochleate and methods of use and manufacture
US20060100226A1 (en) 2004-09-10 2006-05-11 Sikorski James A 2-Thiopyrimidinones as therapeutic agents
BRPI0619252A2 (pt) 2005-11-30 2011-09-20 Vertex Pharma inibidores de c-met e seus usos
DE102005059479A1 (de) * 2005-12-13 2007-06-14 Merck Patent Gmbh Hydroxychinolinderivate
CN101987849B (zh) * 2006-04-14 2013-05-08 普拉纳生物技术有限公司 治疗与年龄相关的黄斑变性(amd)的方法

Also Published As

Publication number Publication date
EP2044026A1 (en) 2009-04-08
WO2007147217A1 (en) 2007-12-27
JP2009541223A (ja) 2009-11-26
EP2044026B1 (en) 2014-03-26
CN101589026A (zh) 2009-11-25
AU2007262670B2 (en) 2012-12-20
AU2007262670A2 (en) 2009-03-26
AU2007262670A1 (en) 2007-12-27
ES2474865T3 (es) 2014-07-09
CN101589026B (zh) 2013-10-16
EP2044026A4 (en) 2009-08-05
CA2656825C (en) 2013-12-10
DK2044026T3 (da) 2014-06-30
CA2656825A1 (en) 2007-12-27
US8163760B2 (en) 2012-04-24
US20100069393A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
JP5415942B2 (ja) 処置の方法およびその処置に有用な薬剤
US8658687B2 (en) Injectable formulations containing asenapine and method of treatment using same
EP2650010A1 (en) Method of treatment or prophylaxis
BRPI0722382A2 (pt) compostos úteis para o tratamento de cáncer
US20110015213A1 (en) Quinazoline derivatives
DK2525796T3 (en) An aqueous solution comprising 3-quinuclidinoner for the treatment of hyperproliferative disease, autoimmune disease and heart disease
US20080293795A1 (en) Combination therapy with parp inhibitors
CN112236140A (zh) 用于癌症治疗的使用异丁司特和第二药剂的方法和剂量方案
TW201808269A (zh) 用於治療搔癢症及／或發癢之方法
EP3849976B1 (en) A gaba a receptor ligand
US6727260B2 (en) Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders
US8518965B2 (en) Compositions and methods for treating cancer
JP5031567B2 (ja) 酵素阻害剤およびその使用
US6340696B1 (en) Viral treatment
CN108066337B (zh) KB-R7943或Bepridil在制备治疗神经胶质瘤的药物中的应用
CN107095871A (zh) Quisinostat，一种新型的高效抗疟药物
RU2337685C2 (ru) Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза
US20220125784A1 (en) Methods and compounds for inhibition of inactivation of voltage-gated sodium channels
HK40057209B (en) A gabaa receptor ligand
Hanover Gribble et al.(45) Date of Patent: Aug. 27, 2013

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110105

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120924

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121220

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130124

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130311

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130607

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130711

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20131028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20131114

R150 Certificate of patent or registration of utility model

Ref document number: 5415942

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees